Related Experiment Video
Updated: Mar 20, 2026
08:56
Evaluation of Lung Metastasis in Mouse Mammary Tumor Models by Quantitative Real-time PCR
Published on: January 29, 2016
10.4K
Evaluating L1CAM expression in human endometrial cancer using qRT-PCR
Sara Notaro1,2, Daniel Reimer1, Michaela Duggan-Peer1
1Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
Oncotarget
|May 28, 2016
Summary
Quantitative real-time PCR (qRT-PCR) reliably assesses L1 cell adhesion molecule (L1CAM) expression in endometrial carcinoma (EC). L1CAM expression predicts distant failure and poor outcomes, while L1CAM promoter methylation indicates reduced lymph-node involvement risk.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Endometrial carcinoma (EC) management requires improved risk stratification.
- L1 cell adhesion molecule (L1CAM) immunohistochemistry (IHC) shows prognostic value in early EC.
- Standardization issues with L1CAM IHC necessitate alternative methods.
Purpose of the Study:
- To validate qRT-PCR as a reproducible method for assessing L1CAM expression in EC.
- To investigate the correlation between L1CAM expression, promoter methylation, and patient outcomes.
- To explore the role of miR-34a in L1CAM regulation.
Main Methods:
- L1CAM expression (L1CAMEXP) analyzed via qRT-PCR in 82 EC and 26 normal endometrium samples.
- L1CAM promoter methylation (L1CAMMET) and miR-34a expression assessed using MethyLight PCR.
- IHC evaluation performed on 50 EC samples for comparison.
Main Results:
- High concordance observed between qRT-PCR and IHC for L1CAM evaluation.
- L1CAMEXP in 11% of EC cases correlated with worse disease-free survival (DFS) and overall survival (OS).
- L1CAMEXP predicted distant failure, while L1CAMMET predicted reduced lymph-node involvement risk.
Conclusions:
- qRT-PCR is a reliable method for evaluating L1CAM status in EC.
- L1CAMEXP is a strong predictor of distant failure and poor prognosis in EC.
- L1CAMMET may serve as a biomarker for pelvic lymph-node involvement risk, requiring further validation.
